Business Context and Reporting Period
This Form 8-K Current Report was filed by Vanda Pharmaceuticals Inc. on June 10, 2014. The report discloses a significant intellectual property event regarding the company's lead product, HETLIOZ (tasimelteon).
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. It is a disclosure of a specific corporate event rather than a financial performance report.
Material Changes and Events
- Patent Allowance: Vanda received a notice of allowance from the United States Patent and Trademark Office (USPTO) for patent application number 13/751,011 (VAND-0092).
- Scope of Protection: The patent covers the method of use of HETLIOZ to treat Non-24-Hour Sleep-Wake Disorder (Non-24), specifically including claims for the totally blind population.
- Orange Book Listing: Vanda intends to submit the patent for listing in the FDA's Orange Book upon issuance.
- Exclusivity Extension: The VAND-0092 patent is expected to expire in 2033. This potentially extends exclusivity for the method of use beyond the expiration of the composition of matter patent, which is currently expected to expire in 2022.
Outlook, Risks, and Forward-Looking Statements
The filing contains forward-looking statements regarding the issuance of the patent and its impact on exclusivity. Management cautions that actual results may differ materially due to risks associated with:
- Actions or inactions by the USPTO and FDA.
- Timing of governmental actions.
- Protection of intellectual property rights.
- Other factors detailed in the company's Form 10-K and Form 10-Q filings.
Vanda explicitly declines any obligation to update these forward-looking statements.
Investor Verification Checklist
- Verify the official issuance date of the VAND-0092 patent by the USPTO.
- Confirm the successful listing of the patent in the FDA Orange Book.
- Monitor for any challenges to the patent validity or scope by competitors.
- Review the company's Form 10-K and 10-Q for detailed risk factors regarding intellectual property.